" class="no-js "lang="en-US"> Bruno Ultra Barcelos is appointed MD of Ethypharm UK
Friday, March 31, 2023

Breaking News

NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions Sensorion Appoints Khalil Barrage as Interim Chairman of the Board Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS) ProJenX Announces Formation of Scientific Advisory Board for Development of ALS Treatment NADclinic Group, BioStarks and Do Not Age Announce Exclusive Partnership to Revolutionise Personalised Longevity PathAI Announces Collaboration with GSK on NASH Phase 2b Clinical Trial Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa Glyscend Therapeutics Appoints Biotech Industry Veteran Michael Wyzga to its Board of Directors
Bruno Ultra BARCELOS is appointed Managing Director of Ethypharm UK | PTF

January 31 2023

Bruno Ultra Barcelos is appointed Managing Director of Ethypharm UK

The Ethypharm Group, a European pharmaceutical company focused on the Central Nervous System and Hospital injectables,  appoints Bruno Ultra Barcelos as Managing Director of its UK subsidiary. Bruno Ultra Barcelos holds an Executive MBA from Kellogg-WHU. He has 30 years of experience in Europe with large international pharmaceutical groups, specialising in both specialities, biosimilars and generic medicines (Schering-Plough, Teva Pharmaceuticals, Novartis Group).

Bruno has held increasingly responsible commercial positions in both sales and marketing, up to General Management positions in Europe. He joins Ethypharm from Sandoz, where he was Country Head for Belgium and Luxembourg. Bruno Ultra Barcelos joins the Ethypharm Group as Managing Director of the Ethypharm UK subsidiary, Ethypharm’s first commercial affiliate, representing 30% of its turnover.

“I am proud to join Ethypharm and very excited about this new challenge. As Managing Director of Ethypharm UK I will continue to foster a growth mindset and focus the teams on the opportunities ahead. I look forward to leading the talented people in place to continue to develop and grow our business, with a focus on the service to our customers and on the safety and quality of our medicines,” says Bruno Ultra Barcelos.

  1. NEC Establishes Subsidiaries in Europe for Strengthening Global AI Drug Development Business

    Drug Development

     Read more
  2. Flare Therapeutics Further Strengthens Leadership Team with Key Executive Appointments and Promotions

    Appointments

     Read more
  3. Sensorion Appoints Khalil Barrage as Interim Chairman of the Board

    Appointments

     Read more
  4. Ablaze Pharmaceuticals Plans Development of Innovative GPC3 Targeted Radiopharmaceutical Therapy for Liver Cancer in Greater China

    Diseases

     Read more
  5. Hansa Biopharma Completes Enrollment in Phase 2 Study of Imlifidase in Guillain-Barré Syndrome (GBS)

    Clinical Trials

     Read more
More On